VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
April 17, 2018 08:00 ET
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationLow-dose study arm: enrollment completeIntermediate-dose study arm: enrollment...
VBI Vaccines Announces Voluntary Delisting from the Toronto Stock Exchange
March 12, 2018 16:15 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. ("VBI" or the "Company") (Nasdaq:VBIV) (TSX:VBV), a commercial-stage biopharmaceutical company developing next-generation...
VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
January 17, 2018 08:00 ET
|
VBI Vaccines, Inc.
Two-part Phase 1/2a study of VBI-1901 to enroll patients with recurrent GBM Part A: Dose escalation to enroll up to 18 patientsPart B: Subsequent extension of optimal dose to enroll up to 10...
VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
December 12, 2017 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will present at the BMO Capital Markets...
VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum
November 02, 2017 08:00 ET
|
VBI Vaccines, Inc.
Ran Nussbaum, managing partner and co-founder of The Pontifax Group, joins VBI Board of DirectorsPontifax’s participation in the recent financing was alongside investments from several new fundamental...
VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares
October 31, 2017 08:30 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...